Evidence map›Paper›PMID 30075765›Full record

Observational studyBMC infectious diseases2018

Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.

Cristina Aurora São Pedro Soeiro, Celina Andreia Melo Gonçalves, Marta Sofia Correia Marques, Maria Josefina Vazquez Méndez, Ana Paula Ribeiro Almeida Tavares, Ana Maria Lacerda Morgado Fernandes de Carvalho de Aboim Horta, Rui Manuel do Rosário Sarmento-Castro

Registry-linked trialOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03965286 (Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03965286 unknown statusnot on this mapstarted 2019, after this paper: background citation

Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital

TypeobservationalSponsorAssiut UniversityRan2019 to 2020Enrolled80ConditionsAntiviral DrugArmsDAAs
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Cristina Aurora São Pedro SoeiroInfectious Diseases Department, Centro Hospitalar do Porto, Largo do Prof. Abel Salazar, 4099-001, Porto, Portugal. cristinaaspsoeiro@hotmail.com.
Celina Andreia Melo GonçalvesInfectious Diseases Department, Centro Hospitalar do Porto, Largo do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Marta Sofia Correia MarquesInfectious Diseases Department, Centro Hospitalar do Porto, Largo do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Maria Josefina Vazquez MéndezInfectious Diseases Department, Centro Hospitalar do Porto, Largo do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Ana Paula Ribeiro Almeida TavaresInfectious Diseases Department, Centro Hospitalar do Porto, Largo do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Ana Maria Lacerda Morgado Fernandes de Carvalho de Aboim HortaInfectious Diseases Department, Centro Hospitalar do Porto, Largo do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Rui Manuel do Rosário Sarmento-CastroInfectious Diseases Department, Centro Hospitalar do Porto, Largo do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Centro Hospitalar do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionConcomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir (TDF) nephrotoxicity, since both these drugs increase TDF levels. Our aim was to evaluate glomerular filtration rate (eGFR) evolution during HCV treatment with sofosbuvir/ledipasvir (SOF/LDV) in HCV/HIV coinfected patients, according to their antiretroviral treatment (ARV).

methodsObservational prospective study of HCV/HIV coinfected patients treated with SOF/LDV. eGFR evolution was evaluated during and 12 weeks after HCV treatment. Patients were categorized in three groups based on ARV regimen: non TDF, non-boosted TDF and TDF + boosted PI.

resultsWe included 273 patients: 145 were receiving a non-TDF regimen, 78 a non-boosted TDF scheme and 50 were receiving TDF + boosted PI. We observed a statistically significant decrease in eGFR during treatment in all groups (non TDF p = 0.03, 95%CI [0.23-3.86], non-boosted TDF p < 0.01, 95%CI [3.36-7.44], TDF + PI p = 0.01, 95%CI [1.09-7.53]). The decrease was more pronounced in those receiving unboosted TDF (- 5.40 ml/min/1.73m

conclusionWe observed a significant decrease in eGFR during treatment in all study groups, that was small and reversible after SOF/LDV discontinuation. TDF was not associated with an increase in renal toxicity.

Indexed as

BenzimidazolesCoinfectionFluorenesHepatitis C, ChronicHIV InfectionsGlomerular Filtration RateHumansProspective StudiesSofosbuvirUridine MonophosphateBenzimidazolesFluorenesledipasvir, sofosbuvir drug combinationSofosbuvirUridine MonophosphateCo-infection HIV/HCVDrug-drug interactionsHCV treatmentProtease inhibitorRenal toxicitySofosbuvir/ledipasvirTenofovir

Identifiers

PMID30075765
PMCPMC6090809
OpenAlexW2885352857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.